Miller, C
Abstract Several peptide dual agonists of the human glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R) are in development for the treatment of type 2 diabetes, obesity and their associated complications
Not all are monitored
All the perfect technique in the world means nothing if the active compound has degraded
IUBMB Life 75(10):856867 Mllerhj MB, Veidal SS, Thrane KT, Or D, Overgaard A, Salinas CG, Madsen MR, Pfisterer L, Vyberg M, Simon E, Broermann A, Vrang N, Jelsing J, Feigh M, Hansen HH (2022) Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH
GLP-1s are no longer a niche health topic